Non-selective β-blockers reduce bacterial translocation by restoring gut barrier function during experimental cirrhosis

Journal of Hepatology · Published 2026-07-01 · DOI 10.1016/j.jhep.2026.07.019

Free full text

Authors (26)

Elisa Castillo, Marco Felber, Lorena Paule, Oriol Juanola, Lorena Wyss, Tim Wolfisberg, Sandro Christensen, Leticia Muñoz, Alejandro Miranda, Manuel Ponce-Alonso, Olaya de Dios, Rosa del Campo, Oscar Pastor, Miguel A. Ortega, Melchor Álvarez-Mon, Tim Rollenske, Sheida Moghadamrad, Andrea de Gottardi, Stephanie Ganal-Vonarburg, Bahtiyar Yilmaz, Val F. Lanza, Eric Felli, Philipp Kellmann, Rubén Francés, Agustín Albillos, Reiner Wiest

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Castillo, E., Felber, M., Paule, L., et al. (2026). Non-selective β-blockers reduce bacterial translocation by restoring gut barrier function during experimental cirrhosis. Journal of Hepatology. https://doi.org/10.1016/j.jhep.2026.07.019

Related articles

• Quantitative Bias Analysis of Unmeasured Confounding Refines Interpretation of Longitudinal Associations Between Cardiometabolic Risk Factors and Liver Stiffness in MASLD · Journal of Hepatology · 2026 · Same journal
• Updates in clinical science: Alcohol-related hepatitis · Journal of Hepatology · 2026 · Same journal
• Low-dose bevacizumab plus atezolizumab enhances transarterial chemoembolization in HCC via correcting vascular-immune niche dysfunction · Journal of Hepatology · 2026 · Same journal
• OSM-STAT3 signaling facilitates Long-term expansion of Pediatric Hepatic Organoids · Journal of Hepatology · 2026 · Same journal
• JHEP at a glance (August 2026) · Journal of Hepatology · 2026 · Same journal
• Before repurposing Fusobacterium nucleatum in alcohol-associated liver disease: it is a rare, non-resident organism in the human alcoholic gut · Journal of Hepatology · 2026 · Same journal
• Declining but persistent hepatocellular cancer risk beyond 10 years of entecavir or tenofovir in chronic hepatitis B: Results of the PAGE-B cohort · Journal of Hepatology · 2026 · Same journal
• Metabolic dysfunction profiles identify heterogeneous hepatocellular carcinoma risk in MASLD-associated advanced fibrosis · Journal of Hepatology · 2026 · Same journal
• Revisiting rejection after immune checkpoint inhibitor exposure prior to liver transplantation for hepatocellular carcinoma · Journal of Hepatology · 2026 · Same journal
• Impact of non-selective beta-blockers on acute kidney injury outcomes in patients with decompensated cirrhosis · Journal of Hepatology · 2026 · Same journal